Joseph J. Eron Jr., MD; Richard Haubrich, MD; Daniel R. Kuritzkes, MD; and Paul E. Sax, MD, discuss the science behind the use of integrase inhibitors, clinical studies of integrase inhibitors, and the role of these agents in managing HIV-infected patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recount findings from basic science that are relevant to the clinical use of integrase inhibitors, including their mechanism of action and the selection of viral resistance
- Describe the results of clinical studies of integrase inhibitors in both treatment-naive and treatment-experienced patient populations including a comparison of these results with those of alternative agents
- Summarize ongoing studies to elucidate the role of integrase inhibitors in novel therapeutic strategies
- Discuss practical strategies to optimize virologic outcomes in patients in whom use of an integrase inhibitor is being considered